Loading...
Implicating androgen excess in propagating metabolic disease in polycystic ovary syndrome.
Kempegowda, Punith Melson, Eka Manolopoulos, Konstantinos N Arlt, Wiebke O'Reilly, Michael W
Kempegowda, Punith
Melson, Eka
Manolopoulos, Konstantinos N
Arlt, Wiebke
O'Reilly, Michael W
Citations
Altmetric:
Advisors
Editors
Other Contributors
Departments
Date
2020-06-24
Date Submitted
Keywords
C11-oxy C19 androgens
PCOS
adipose tissue
androgens
DIABETES
metabolic disease
OBESITY
PCOS
adipose tissue
androgens
DIABETES
metabolic disease
OBESITY
Other Subjects
Subject Mesh
Planned Date
Start Date
Collaborators
Principal Investigators
Files
Loading...
2042018820934319.pdf
Adobe PDF, 625.77 KB
Alternative Titles
Publisher
Abstract
Polycystic ovary syndrome (PCOS) has been traditionally perceived as a reproductive disorder due to its most common presentation with menstrual dysfunction and infertility. However, it is now clear that women with PCOS are at increased risk of metabolic dysfunction, from impaired glucose tolerance and type 2 diabetes mellitus to nonalcoholic fatty liver disease and cardiovascular disease. PCOS is characterised by androgen excess, with cross-sectional data showing that hyperandrogenism is directly complicit in the development of metabolic complications. Recent studies have also shown that C11-oxy C19 androgens are emerging to be clinically and biochemically significant in PCOS, thus emphasising the importance of understanding the impact of both classic and C11-oxy C19 androgens on women's health. Here we discuss androgen metabolism in the context of PCOS, and dissect the role played by androgens in the development of metabolic disease through their effects on metabolic target tissues in women.
Language
en
Citation
ISSN
2042-0188
eISSN
ISBN
DOI
10.1177/2042018820934319
PMID
32637065